• Interview with CEO: Development throught toxicology and safety studies

    CEO Martin Vidaeus explains about development through toxicology and safety studies. About RP101 RP101 is the company’s main development program of a new treatment of chronic dry eye disease in postmenopausal women. The active substance is a molecule that has already shown safety and efficacy in two clinical phase II studies conducted in the United […]

  • Redwood Pharma starts production of RP101 for clinical trials

    Following successfully completed toxicology and safety studies, Redwood Pharma has now started production of the drug RP101 for use in the forthcoming Phase II clinical trial. This is another important milestone in the development of RP101, the first therapy for treatment of moderate to severe dry eye in postmenopausal women. Production of material for the […]

  • Toxicology and Safety Studies are Successfully Completed

    Redwood Pharma AB (publ) announces that the RP101 toxicology studies are now successfully completed. The Company can thereby continue the development of RP101 and approach the next goal of starting the clinical Phase II study in patients with chronic dry eye disease. Safety studies are a critical step in the development of a pharmaceutical. Redwood […]

  • Redwood Pharma to Attend Bio-Europe 2017, Nov. 6 – 8 in Berlin for Partnering Discussions

    Redwood Pharma will be attending Bio-Europe 2017 in Berlin, Nov. 6 – 8 to meet and continue discussions with potential pharmaceutical partners regarding co-development and licensing of RP101, the Company’s therapy to treat chronic dry eye disease in postmenopausal women and the IntelliGel drug delivery platform. RP101 is the Company’s lead program for the development […]

  • Redwood Pharma enters into agreement with CRO for clinical trial

    Redwood Pharma AB (publ) has contracted the Swiss contract research organization (CRO) CROss Alliance® for the management of a clinical phase II trial in patients with chronic dry eye disease. The clinical trial will be performed in Europe where CROss Alliance is well-established and has earlier successfully executed several studies within ophthalmology. The agreement with […]

  • Redwood Pharma begins production of active ingredient in RP101 for Phase II studies

    Medicines that are used in clinical trials are stringently regulated. Regulated production begins now of the active pharmaceutical ingredient in RP101, which will be used in the clinical Phase II trial scheduled for the coming fall. RP101 is a new medical treatment for post-menopausal women suffering from chronic dry eye disease. Medicines used in clinical […]

  • Redwood Pharma initiates toxicological safety studies

    Redwood Pharma AB (publ) now begins toxicological safety studies for its drug development project RP101. The results will initially be incorporated into the Company’s application for permission to perform the clinical Phase II trial, which represents the next stage of development for RP101. Development work continues according to plan. The Company’s drug development project RP101, […]

  • New US patent approved

    Redwood Pharma’s licensor, Broda Technologies, has been granted an additional patent in the US regarding the IntelliGel drug delivery platform. The new patent is maximally valid until 21 March 2031 and represents additional protection of IntelliGel, which in turn becomes even more commercially attractive in the US market for prescription-based pharmaceuticals applied to the eye. […]

  • Redwood Pharma AB (publ) End of Year Report 2016

    Redwood Pharma AB (publ), End of Year Report 2016 January – December 2016. The period January 1 – December 31, 2016 • Net Revenues KSEK 0 (0) • Operating Loss KSEK -8 736 (-166) • Loss per Share SEK -1,75 (-14,90) 2016 Fourth Quarter (October 1 – December 31) • Net Revenues KSEK 0 (0) […]

  • Eye expert to support Redwood Pharma

    In preparation for the upcoming pharmaceutical clinical trial of RP101, Redwood Pharma AB (publ) has retained Associate Professor Gerhard Garhöfer of the Medical University of Vienna as a medical advisor. Professor Garhöfer is a leading expert in ophthalmology in Europe and has extensive experience in treating patients with Dry Eye Disease. Professor Garhöfer is currently […]